The Effect of Bevacizumab (Avastin) on Pterygium

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00592176
First received: December 26, 2007
Last updated: May 21, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to determine whether local injection of bevacizumab might halt and or cause regression of pterygium growth. This may enable earlier treatment and prevention of pterygium growth into the patient's line of sight thereby limiting the need for surgery and improving quality of life for patients with pterygia.


Condition Intervention Phase
Pterygium
Drug: local injection of bevacizumab
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effect of Bevacizumab (Avastin) on Pterygium

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • To Determine Whether Injection of Bevacizumab Might Halt and or Cause Regression of Pterygium Growth. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Determining the number of patients having progression or regression of their pterygium after receiving bevacizumab treatment of their pterygium.


Secondary Outcome Measures:
  • Number of Patients Having Surgical Removal of Pterygium. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The number of patients having surgical removal of pterygium within 12 months.


Enrollment: 6
Study Start Date: August 2007
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: local injection of bevacizumab
    Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 19 years of age and older
  • Diagnosis of pterygia
  • healthy enough to make scheduled follow-up visits

Exclusion Criteria:

  • Women of childbearing potential and males who plan to father a child during their participation in the study will be excluded from the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00592176

Locations
United States, Alabama
Callahan Eye Foundation Hospital
Birmingham, Alabama, United States, 35233
Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
Principal Investigator: Tyler A Hall, MD University of Alabama at Birmingham
  More Information

No publications provided

Responsible Party: University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT00592176     History of Changes
Other Study ID Numbers: F070323011
Study First Received: December 26, 2007
Results First Received: May 21, 2012
Last Updated: May 21, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Pterygium
Conjunctival Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 15, 2014